Kadri Altundag

Kadri Altundag

Auto-generated profile, based on publicly available information

Kadri Altundag

Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2004 in Cancer
Verified
Journal Article
Open access
PDF file
PMPaolo Morandi
Paolo Morandi
RRRoman Rouzier
Roman Rouzier
KAKadri Altundag
Kadri Altundag
ABAman U. Buzdar
Aman U. Buzdar
RTRichard L. Theriault
Richard L. Theriault
GHGabriel Hortobagyi
Gabriel Hortobagyi
BACKGROUND The authors examined the published evidence on the use of aromatase inhibitors (AIs) in the adjuvant setting in postmenopausal, hormone receptor–positive patients, and they provide recommendations for clinical management in 3 different situations: newly diagnosed women, women who have already received tamoxifen for 2–3 years, and women who have completed 5‐years of tamoxifen and are disease free. METHODS All double‐blind, randomized, prospective studies were reviewed. Data sources included the MEDLINE data base, reviews, editorials, and experts. RESULTS The Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, the Intergroup Exemestane Study (IES), and the MA‐17 trial confirmed the superiority of AIs over tamoxifen in women with early‐stage breast carcinoma, improving disease‐free survival (DFS) considerably. In the ATAC trial, the 4‐year DFS rate was 86.9% on anastrozole and 84.5% on tamoxifen (P = 0.03); in the IES, the 3‐year DFS rate was 91.5% on exemestane and 86.8% on tamoxifen (P = 0.00005); and, in MA‐17, the 4‐year estimated DFS rate was 93% on letrozole and 87% on placebo (P ≤ 0.001). All studies were limited because of the immaturity of data, particularly concerning long‐term safety. A negative impact on bone health was observed in all three trials. However short‐term side effects were acceptable. In addition, the studies demonstrated a significant reduction in the frequency of new primary tumors in the contralateral breast. CONCLUSIONS Current data support anastrozole as first‐line adjuvant hormonal therapy, or a change to AIs after 2–3 years of tamoxifen, or the use of letrozole at the end of a 5‐year course of tamoxifen as first‐choice treatment options for the management of hormone receptor–positive breast carcinoma in postmenopausal women. Ongoing clinical trials should help to define the precise timing, duration, and sequencing of AI therapy, in addition to the long‐term tolerability profile and potential differences between anastrozole, letrozole, and exemestane. Cancer 2004. © 2004 American Cancer Society.

1 January 2004 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
KAKadri Altundag
Kadri Altundag
ODOguz Dikbas
Oguz Dikbas
BOBasak Oyan
Basak Oyan
AUAlp Usubutun
Alp Usubutun
ATAlev Turker
Alev Turker

28 July 2015
Verified
Journal Article
Closed access
MSMustafa Solak
Mustafa Solak
FTFatma P Turkoz
Fatma P Turkoz
OKOzge Keskin
Ozge Keskin
SASercan Aksoy
Sercan Aksoy
TBTaner Babacan
Taner Babacan
KAKadri Altundag
Kadri Altundag

1 January 2004 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
KAKadri Altundag
Kadri Altundag
SASercan Aksoy
Sercan Aksoy
IGIbrahim Gullu
Ibrahim Gullu
OAOzden Altundag
Ozden Altundag
EOEnis Ozyar
Enis Ozyar
FAFadil Akyol
Fadil Akyol

1 January 2005 in Medical Hypotheses
Verified
Journal Article
Closed access
RIRabiul Islam
Rabiul Islam
KAKadri Altundag
Kadri Altundag
MKMevlut Kurt
Mevlut Kurt
OAOzden Altundag
Ozden Altundag
STSelahattin Turen
Selahattin Turen

27 January 2015 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
MSMehmet Ali Nahit SENDUR
Mehmet Ali Nahit SENDUR
SASercan Aksoy
Sercan Aksoy
HYHikmet Yorgun
Hikmet Yorgun
NONuriye Ozdemir
Nuriye Ozdemir
FYFatma Meric Yilmaz
Fatma Meric Yilmaz
KAKadri Altundag
Kadri Altundag
Trastuzumab induced cardiotoxicity (TIC) was defined as the most serious side effect. Long term cardiac effects of trastuzumab are still not known, thus we aimed to compare the long term cardiac effects of adjuvant trastuzumab therapies of HER2-positive breast cancer according to the treatment duration.Patients who completed adjuvant trastuzumab treatment at least 6 months before for the adjuvant setting in HER2-positive breast cancer were included in the study. A total of 164 patients were included in this study: 108 and 56 patients were treated with 9 weeks and 52 weeks of trastuzumab, respectively. The main limitation of our study is that due to the cross-sectional evaluation of cardiac biomarkers we cannot predict the status of baseline cardiac biomarkers of this population.The median follow-up of the study was 32 (10-95) months. The accompanying chronic diseases were similar in both groups. Baseline left ventricular ejection fraction (LVEF) was 65.5 ± 3.4% vs 67.1 ± 4.5% in the 9 weeks and 52 weeks trastuzumab treatment groups, respectively (p = 0.13). Symptomatic heart failure was not observed during trastuzumab treatment in either group. Trastuzumab induced cardiotoxicity (TIC) was observed in 2 (1.9%) and 17 (30.3%) patients in the 9 and 52 weeks trastuzumab treatment groups, respectively (p < 0.001). After a median 24 months of follow-up from the last dose of trastuzumab, mean LVEF values were similar between the two treatment arms (p = 0.29). In the subgroup analyses, mean LVEF values were significantly lower in patients who developed TIC compared to those who did not develop TIC (61.9 ± 3.6% vs 64.4 ± 2.6%, p = 0.04). Average mean LVEF loss from baseline was significantly higher in patients who developed TIC compared to those who did not develop TIC (10.0 ± 6.0% vs 1.5 ± 6.2%, p < 0.001). Cardiac biomarkers were similar in both treatment groups. In the subgroup analyses serum High-sensitivity C-reactive protein (hs-CRP) and prohormone brain natriuretic peptide (pro-BNP) levels were significantly higher in patients who developed TIC compared to those who did not develop TIC.TIC was observed to be significantly higher in the 52 weeks trastuzumab group. At the end of 32 months of follow-up mean LVEF values and cardiac biomarkers were similar between the two treatment groups. In the subgroup analyses, significant LVEF loss and higher cardiac biomarkers which show cardiac damage in patients who developed TIC can be permanent in some of the patients and long term cardiac damage may be underestimated.